ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX · Real-Time Price · USD
1.720
-0.030 (-1.71%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc.
| Country | Canada |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | David Parkinson |
Contact Details
Address: 999 West Broadway, Suite 720 Vancouver, BC V5Z 1K5 Canada | |
| Phone | (778) 331-0962 |
| Website | essapharma.com |
Stock Details
| Ticker Symbol | EPIX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001633932 |
| CUSIP Number | 29668H708 |
| ISIN Number | CA29668H7085 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Ross Parkinson M.D. | President, Chief Executive Officer and Director |
| David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA | Chief Financial Officer |
| Peter A. Virsik M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Alessandra Cesano M.D., Ph.D. | Chief Medical Officer and Executive Vice President |
| Chandtip Chandhasin | Executive |
| Erica Osbourne | Executive |
| Erin Rudsinski | Executive |
| Loleta Harris | Executive |
| Neil Thapar | Executive |
| Nkengyal Barber | Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | 8-K | Current Report |
| Feb 11, 2025 | 10-Q | Quarterly Report |
| Jan 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 22, 2025 | DEF 14A | Other definitive proxy statements |
| Dec 17, 2024 | 8-K | Current Report |